Looking Ahead from EASD: Sinocare’s Innovative CGM and AI Applications Drive Global Diabetes Management Transformation

From September 9 to 13, 2024, the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) was held in Madrid, Spain. As one of the most influential international conferences in the field of diabetes, the EASD Annual Meeting brought together leading diabetes researchers, clinicians, scientists, and industry leaders to discuss the latest advancements in diabetes research and the future trends in diabetes management.

Following the 2023 EASD meeting in Hamburg, Sinocare once again hosted an academic symposium with a global impact. During the symposium, Sinocare presented the latest clinical data for its iCan real-time CGM system, as well as the company’s strategy for integrating AI into digital diabetes management, through four in-depth speeches. Additionally, Sinocare invited top global industry leaders Dr. Lutz Heinemann, Dr. Guido Freckmann, and Dr. Marc Breton to engage in in-depth discussions on the current state of diabetes management and future trends, showcasing Sinocare’s important role in driving cutting-edge exploration in the field of diabetes management.

iCan CGM System: Excellent and Stable Trial Data in Pediatric Clinical Study

At the symposium, Dr. Zheng Jiyun, Sinocare’s Vice President, shared the latest progress of the multi-center clinical trials of the iCan CGM System conducted in China, specifically focusing on children. In this study, 89% of the subjects were diagnosed with Type 1 diabetes. The clinical data from the first 60 patients showed that the mean absolute relative difference (MARD) of iCan CGM was approximately 8.6%, and it consistently maintained a single-digit MARD level across different blood glucose concentration ranges and throughout the 15-day wearing period.

According to the Clarke Error Grid (CEG) analysis, 100% of the paired data points fell into the A+B zones of the CEG, with 96% in the A zone. These results were highly consistent with adult clinical trial data, indicating that the iCan CGM achieves internationally leading accuracy in pediatric patients. No adverse events related to the device were reported throughout the study, and patients highly rated their experience with the iCan CGM.

In-Depth Exploration of CGM Accuracy Assessment

To further explore the assessment of CGM accuracy, Sinocare invited renowned German expert, Professor Guido Freckmann, to share his insights. Based on extensive research data, Professor Freckmann emphasized the necessity for standardizing various influencing factors in study designs to ensure the improvement of device performance.

Professor Freckmann also pointed out that differences in the data traceability systems and calibration methods used in studies could impact the accuracy of CGM devices. Therefore, promoting consistency and standardization in research would help enhance the overall performance of CGM devices, ensuring their reliability and comparability in clinical applications.

AID Systems: The Intelligent Future of Diabetes Management

CGM is a key component in the development of Artificial Pancreas (AID) systems. Sinocare invited Professor Marc Breton from the University of Virginia to share his innovations in the artificial pancreas field. In response to Professor Freckmann’s points, Professor Breton stated that the accuracy of CGM significantly impacts insulin infusion in AID systems, thereby affecting treatment outcomes. He emphasized that next-generation AID systems, particularly Fully Closed Loop (FCL) algorithms, aim to overcome the limitations of current hybrid closed-loop systems. He also presented interim data for the FCL AIDANET algorithm after one week. Overall, after patients transitioned to home care for seven days, their Time in Range (TIR) using the FCL system reached 70%, which was 7% higher than the 63% TIR observed with conventional care using hybrid closed-loop algorithms.

AI-Driven Diabetes Digital Management: Sinocare’s Practice and Outlook

Lastly, Dr. Fei Jiangfeng, Head of Sinocare CGM Business Unit, provided a detailed introduction to how the company is leveraging AI technology in the digital management of diabetes. He shared Sinocare’s innovative practices in building a comprehensive diabetes management model, which includes enhancing patients’ self-management abilities and optimizing the distribution of medical resources. For example, Sinocare developed a “Virtual Diabetes Ward” that uses trained language models combined with Electronic Health Record (EHR) data to offer personalized treatment advice for hospitalized patients. Additionally, Dr. Fei mentioned that Sinocare is integrating CGM data with patients’ voice memos and meal photos, using this information to provide dynamic behavioral and dietary recommendations. These practices demonstrate Sinocare’s innovative vision for AI-driven diabetes management, further advancing personalized healthcare management and the efficient use of medical resources.

Through this important academic symposium successfully hosted by Sinocare, the company showcased its innovative achievements and future plans in the field of digital diabetes management. This series of academic exchanges and data presentations highlighted Sinocare’s core position in advancing the cutting edge of diabetes management technology, as well as its leadership role in global diabetes management innovation.